Estrogens and postprandial lipid metabolism

Atherosclerosis

Volumn 141, Issue SUPPL. 1, 1998, Pages

  Westerveld, H E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Coronary artery disease; Estrogen; Postprandial lipid metabolism

Indexed keywords

APOLIPOPROTEIN B48; CHYLOMICRON; ESTRADIOL; ESTROGEN; LIPID; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HORMONE SUBSTITUTION; HUMAN; LIPID METABOLISM; POSTPRANDIAL STATE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031774401     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00227-5     Document Type: Conference Paper

References (25)

1. Barrett Connor E, Bush TL. Estrogen and coronary heart disease in women. J Am Med Assoc 1991;265:1861-7.
2. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. New Engl J Med 1997;336:1769-75.
3. Williams JK, Shively CA, Clarkson TB. Determinants of coronary artery reactivity in premenopausal female cynomolgus monkeys with diet-induced atherosclerosis. Circulation 1994;90:983-7.
4. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17β-estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 1990;10:1051-7.
5. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:217-21.
6. Williams JK, Honore EK, Washburn SA, Clarkson TB. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol 1994;24:1757-61.
7. McFarland KF, Boniface ME, Hornung CA, Earnhardt W, Humphries JO. Risk factors and noncontraceptive estrogen use in women with and without coronary disease. Am Heart J 1989;117:1209-14.
8. Sullivan JM, El Zeky F, Vander Zwaag R, Ramanathan KB. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol 1997;79:847-50.
9. Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinski KA. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J 1988;115:954-63.
10. Morise AP, Dalal JN, Duval RD. Value of a simple measure of estrogen status for improving the diagnosis of coronary artery disease in women. Am J Med 1993;94:491-6.
11. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO. Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women. Am J Cardiol 1995;75:264-8.
12. Beale CM, Collins P. The menopause and the cardiovascular system. Baillieres Clin Obstet Gynaecol 1996;10:483-513.
13. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. J Am Med Assoc 1995;273:199-208.
14. Patsch JR, Miesenbock G, Hopferwieser T, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 1992;12:1336-45.
15. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994;106:83-97.
16. Groot PH, van Stiphout WA, Krauss XH, et al. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb 1991;11:653-62.
17. Weintraub MS, Grosskopf I, Rassin T, et al. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years. Br Med J 1996;312:936-9.
18. Meyer E, Westerveld HT, de Ruyter Meijstek FC, et al. Abnormal postprandial apolipoprotein B-48 and triglyceride responses in normolipidemic women with greater than 70% stenotic coronary artery disease: a case-control study. Atherosclerosis 1996;124:221-35.
19. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Postprandial plasma lipoprotein changes in human subjects of different ages. J Lipid Res 1988;29:469-79.
20. Berr F, Eckel RH, Kern F Jr. Contraceptive steroids increase hepatic uptake of chylomicron remnants in healthy young women. J Lipid Res 1986;27:645-51.
21. Stuyt PM, Demacker PN, van't Laar A. A study of the hypolipidemic effect of estrogen in type III hyperlipoproteinemia. Horm Metab Res 1986;18:607-10.
22. Kushwaha RS, Hazzard WR, Gagne C, Chait A, Albers JJ. Type III hyperlipoproteinemia: paradoxical hypolipidemic response to estrogen. Ann Intern Med 1977;87:517-25.
23. Westerveld HT, Kock LA, van Rijn HJ, Erkelens DW, de Bruin TW. 17β-Estradiol improves postprandial lipid metabolism in postmenopausal women. J Clin Endocrinol Metab 1995;80:249-53.
24. Westerveld HT, Meijer E, Erkelens DW, de Bruin TW. Postprandial reduction in high-density lipoprotein cholesterol concentrations in postmenopausal women: improvement by 17β-estradiol. Metabolism 1996;45:827-32.
25. de Bruin TW, Brouwer CB, Gimpel JA, Erkelens DW. Postprandial decrease in HDL cholesterol and HDL apo A-I in normal subjects in relation to triglyceride metabolism. Am J Physiol 1991;260:492-8.